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Summary 
Background Faltered linear growth and pubertal delay, which are both common in children with HIV in sub-Saharan 
Africa, might affect adolescent bone accrual and future fragility fracture risk. We investigated the association of HIV 
with bone density adjusted for skeletal size in peripubertal children in Zimbabwe.
Methods We did a cross-sectional study of baseline data from the IMVASK cohort, which enrolled children aged 
8–16 years with HIV who had been taking antiretroviral therapy (ART) for at least 2 years, and children of the same 
age without HIV. Children with HIV were recruited from public sector HIV clinics at Parirenyatwa General Hospital 
and Harare Central Hospital (Harare, Zimbabwe), and children without HIV were recruited from six schools in the 
same suburbs that the hospitals serve. Sociodemographic, clinical, and anthropometric data were collected. 
Dual-energy X-ray absorptiometry (DXA) was used to measure the bone outcomes of total-body less-head bone 
mineral content for lean mass adjusted for height (TBLH-BMCLBM), and lumbar spine bone mineral apparent density 
(LS-BMAD), and we assessed the prevalence of low TBLH-BMCLBM and low LS-BMAD (defined by Z-scores of less 
than –2·0). Size adjustment techniques were used to overcome the size dependence of DXA measurement. We used 
linear regression models, with multiple imputation for missing data, to assess relationships between risk factors and 
TBLH-BMCLBM and LS-BMAD Z-scores in children with and without HIV.
Findings We recruited 303 children with HIV (mean age 12·4 years [SD 2·5]; 151 [50%] girls) and 306 children without 
HIV (mean age 12·5 years [SD 2·5]; 155 [51%] girls). In children with HIV, median age of HIV diagnosis was 3·0 years 
(IQR 1·2–5·8), and median ART duration was 8·1 years (6·2–9·5); for 102 (34%) children, ART included tenofovir 
disoproxil fumarate (TDF). Children with HIV had a higher prevalence of low TBLH-BMCLBM Z-score than children 
without HIV (29 [10%] of 279 children with available data vs 18 [6%] of 292 with available data; p=0·066) and a higher 
prevalence of low LS-BMAD Z-score (40 [14%] of 279 vs 17 [6%] of 293 with available data; p=0·0007). HIV and male 
sex were associated with earlier pubertal (Tanner) stage. The negative associations between HIV and Z-scores for 
TBLH-BMCLBM and LS-BMAD were more pronounced with pubertal maturation, particularly in girls. Among children 
with HIV, TDF exposure and orphanhood were associated with lower TBLH-BMCLBM Z-score in confounder-adjusted 
analysis. Current TDF use (vs non-TDF-based ART) was associated with a reduction in TBLH-BMCLBM Z-score of 0·41 
(95% CI 0·08–0·74; p=0·015) and in LS-BMAD Z-score of 0·31 (0·08–0·69; p=0·12).
Interpretation Despite ART, HIV is associated with substantial skeletal deficits towards the end of puberty. The extent 
of bone deficits associated with TDF and its widespread use in children in sub-Saharan Africa are a concern for future 
adult fracture risk.
Funding Wellcome Trust.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Stunting and delayed puberty are common manifestations 
of perinatally acquired HIV infection; in low-resource 
settings up to 50% of children with HIV have poor linear 
growth.1 In sub-Saharan Africa, where 90% of the world’s 
children with HIV live, high background rates of mal-
nutrition and intercurrent infections further impair linear 
growth, such that the prevalence and extent of stunting is 
markedly higher than in high-income settings.1,2 Puberty 
is a crucial period for bone mass accrual; after cessation of 
linear growth, consolidation of mineral continues until 
peak bone mass (PBM) is reached in early adulthood, 
serving as a reservoir of bone for later life. Therefore, 
disturbances in growth or pubertal delay due to HIV 
infection have implications for bone mass accrual and 
PBM. Low PBM is a principal determinant of subsequent 
adult osteo porotic fracture risk; a 10% reduction in PBM 
doubles fracture risk in adulthood.3
The scale-up of antiretroviral therapy (ART) programmes 
globally has substantially improved the survival of 
people with HIV, and increasing numbers of children 
with HIV—who would otherwise have died in early 
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childhood—are surviving to adolescence and adulthood.4 
Catch-up linear growth occurs once ART is initiated, but 
individuals who start ART in late childhood might not 
realise their full growth potential or attain population age 
growth norms.5 In sub-Saharan Africa, children start 
ART later than in high-income settings, at 7·9 years 
(IQR 6·0–9·3) compared with 0·9 years (IQR 0·4–2·6) in 
North America.6 Furthermore, the prevalence of stunting 
is higher in sub-Saharan Africa, meaning HIV might have 
a more detrimental effect on skeletal growth than in high-
income settings.2 Notably, small cross-sectional studies 
from South Africa have shown reduced bone mass7 and 
strength8 in mostly prepubertal children with HIV.
Most studies investigating the effect of HIV infection 
on skeletal growth have been done in high-income 
settings and have not taken into account the effect of 
poor growth on bone density.9 Dual energy X-ray 
absorptiometry (DXA) is commonly used to measure 
bone density; however, when skeletons are small (in the 
case of HIV, due to stunting), DXA underestimates bone 
density,10 and therefore adjustment for skeletal size is 
important in paediatric populations. Our aim was to 
understand the relationship between HIV infection and 
skeletal health in peripubertal children on ART in 
Zimbabwe, as a country with a generalised and sustained 
severe HIV epidemic. Specifically, we sought to identify 
the prevalence of low bone density adjusted for skeletal 
size in children with and without HIV, and to investigate 
risk factors associated with reduced size-adjusted bone 
density.
Methods 
Study design and participants 
We did a cross-sectional study using baseline DXA bone 
measurements from the IMVASK study, which is a 
prospective cohort study on the impact of vertical HIV 
infection on child and adolescent skeletal development in 
Harare, Zimbabwe. The IMVASK protocol has been 
published elsewhere (ISRCTN registry ISRCTN12266984)11 
and 12-month follow-up has been completed. Children 
Bristol Medical School, 
University of Bristol, Bristol, UK 
(Prof C L Gregson FRCP)
Correspondence to: 
Dr Ruramayi Rukuni, Biomedical 




Evidence before this study
We and others have previously shown that faltered linear 
growth resulting in stunting is common in children with HIV in 
sub-Saharan Africa. Successful roll-out of antiretroviral therapy 
(ART) programmes has enabled increased numbers of children 
to survive adolescence and reach adulthood. Puberty is a crucial 
period of skeletal development, during which bone mass 
accrues to achieve, by early adulthood, peak bone mass, which 
has been shown to be a key determinant of lifetime fracture 
risk. We searched Embase, Ovid MEDLINE(R) (including Epub 
Ahead of Print and Daily databases), Cochrane Library, 
and conference proceedings (through Web of Science) from 
inception until March 10, 2021, adapting search strategies for 
each database to include combinations of medical subject 
headings (MeSH terms) relevant to bone growth, development, 
HIV, and ART in children, without language restrictions. 
Few studies had investigated the effect of HIV on adolescent 
skeletal growth in low-income settings and even fewer had 
adequately considered the effect of skeletal size on bone density 
measurement techniques; consideration of skeletal size is 
crucial as the most commonly used measure, dual energy X-ray 
absorptiometry (DXA), underestimates bone density when 
skeletons are small (as is the case with stunting). 
The International Society for Clinical Densitometry (ISCD) has 
recommended specific size-adjustment techniques to overcome 
this problem. These techniques had not been used to 
understand the effect of HIV on bone mass accrual in 
populations in sub-Saharan Africa.
Added value of this study
To our knowledge, this study is the largest to investigate the 
effect of HIV infection on skeletal health in children (aged 
8–16 years) in sub-Saharan Africa. Our findings are 
strengthened by use of the ISCD-recommended 
size-adjustment methods for DXA data, which was particularly 
important given the observed height differences (levels of 
stunting) in our study population. We found that marked 
deficits in bone density were common in children with HIV, who 
had a substantially higher prevalence of low bone density 
(a deficit of 2 SDs or more) than their HIV-uninfected peers. 
The effect of HIV on bone density was most marked in the late 
stages of puberty, especially in girls. Use of tenofovir disoproxil 
fumarate (TDF) was strongly associated with bone deficits, 
particularly affecting the total body (predominantly reflecting 
cortical bone). TDF exposure for 4 or more years was associated 
with a 0·52 SD deficit in total body Z-score, which translates 
clinically to an approximately 50% increase in fracture risk in 
childhood and, if sustained, adulthood.
Implications of all the available evidence
This study highlights the importance of addressing the 
long-term adverse effects of HIV infection on musculoskeletal 
health in children living in sub-Saharan Africa. If the type of 
bone deficits we identified persist into adulthood, this African 
region is at risk of increased fracture incidence, particularly 
within the current birth cohort. The finding that bone mineral 
deficits appear greatest at the end of puberty in girls is of 
concern, as girls are likely to depend on potentially inadequate 
skeletal calcium reserves to support pregnancy and lactation in 
adulthood, which might increase their risk of vertebral fracture. 
TDF is currently one of the recommended component drugs of 
a first-line ART regimen in children of sufficient age and weight 
(as well as in adults), and is thus extensively used in 
sub-Saharan Africa, sometimes even in children who do not 
quality for its use when other options are not available. 
The detrimental effects associated with TDF use in this study 
support re-evaluation of its first-line use during skeletal 
growth.
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aged 8–16 years with HIV were recruited from outpatient 
HIV clinics at the only two public sector general hospitals 
in Harare (Parirenyatwa General Hospital and Harare 
Central Hospital). Studies in children suggest that ART 
initiation is followed by an initial decrease in bone mass, 
which stabilises after 2 years,12 and therefore we enrolled 
children with HIV who had been taking ART for at least 
2 years. Systematic quota-based sampling, stratified by 
age and sex, was used to recruit 50 male children and 
50 female children in each of three age groups (8–10 years, 
11–13 years, and 14–16 years). Exclusion criteria were 
being acutely unwell (defined as requiring immediate 
hospitalisation), not residing in Harare, and being 
unaware of one’s HIV status (to avoid inadvertent dis-
closure during study participation). A maximum of 
five children with HIV were recruited each day for 
logistical reasons.
A comparison group of children without HIV was 
recruited from six government primary and secondary 
schools randomly selected from the 109 primary schools 
and 44 secondary schools within the same suburbs in 
Harare where the hospitals provide HIV care. A random 
number sequence was computer-generated and applied 
to a list provided by the Ministry of Primary and Secondary 
Education of all schools in the area. Schools were 
approached in sequence to seek consent. Schools which 
declined to participate were replaced by schools on a 
reserve list until the target of six schools was reached. 
Younger children (8–12 years) were sampled from 
primary schools and older children (14–16 years) from 
secondary schools, with children aged 13 years sampled 
from both schools. The number of children selected from 
each school was proportional to school size, thereby 
giving each child equal probability of being sampled. We 
applied a random number sequence to school registers to 
select participants using the same quota-based sampling 
approach of 50 male children and 50 female children in 
each of the three age strata. Letters were sent to the 
households of children who had been randomly selected. 
Children underwent HIV testing after enrolment; those 
testing positive and not in care were referred to HIV 
services. Children in schools who tested positive were 
considered for enrolment in the HIV cohort.
Ethical and governance approvals were granted by the 
ethics committee of the London School of Hygiene & 
Tropical Medicine (London, UK; reference 15333), the 
institutional review board of the Biomedical Research and 
Training Institute in Harare (reference AP145/2018), the 
joint research ethics committee for the University of 
Zimbabwe College of Health Sciences (Harare) and the 
Parirenyatwa Group of Hospitals (Harare; reference 11/18), 
the Harare Central Hospital ethics committee (reference 
170118/04), the Medical Research Council of Zimbabwe 
(Harare; reference MRCZ/A/2297), and the Ministry of 
Primary and Secondary Education of the Government 
of Zimbabwe (Harare; reference C/426/Harare). Parents 
or guardians provided written informed consent for study 
participation and HIV testing, and children provided 
written assent.
Procedures 
All data in this study were collected at recruitment 
(baseline) in the IMVASK study, from May 4, 2018, to 
Jan 21, 2020. A questionnaire administered by research 
staff was used to collect sociodemographic and clinical 
data, including smoking status and alcohol and steroid 
use, from children in the company of a parent or 
guardian (with parents and guardians allowed to answer 
questions on the child’s behalf). The International 
Physical Activity Questionnaire, validated in multiple 
countries including South Africa but not Zimbabwe, 
was used to assess physical activity as multiples of the 
resting metabolic rate (MET) in MET minutes. Diet and 
nutrition were assessed with a tool that was based on a 
validated dietary diversity and food frequency tool from 
India and Malawi,13 and adapted to the Zimbabwean 
context with international guidelines applicable to sub-
Saharan Africa.14 This tool quantified dietary calcium 
and vitamin D intake plus sunlight exposure; adaptations 
reflected the Zimbabwean context in which fortification 
of oils and margarine with vitamin D is mandated and 
specific vitamin D rich foods, such as Kapenta fish, are 
commonly eaten.
Anthropometric measurements were done by trained 
research nurses and research assistants at the study 
clinics. Standing and sitting height, which was measured 
to the nearest 0·1 cm (with a Seca 213 stadiometer; Seca, 
Hamburg, Germany), and weight, which was measured 
to the nearest 0·1 kg (with Seca 875 weight scales), were 
recorded by two separate readers. If height measurements 
differed by more than 0·5 cm, or weight measurements 
by more than 0·5 kg, a third reading was taken by an 
additional reader, and final height and weight values 
were taken as means of the two or three measurements. 
The same staff measured the children with and without 
HIV. All equipment was calibrated annually. Tanner 
pubertal staging was done by a nurse and doctor, with an 
orchidometer used to assess testicular volume in males. 
Pubertal delay was defined as not having reached Tanner 
stage 2 in girls aged 13 years or older, and in boys aged 
14 years or older.
Details collected for participants with HIV were age at 
HIV diagnosis, probable mode of transmission, ART 
regimen and duration, and current CD4 cell count and 
HIV viral load. CD4 cell count was measured with an 
Alere PIMA CD4 Analyser (Waltham, MA, USA) and 
HIV viral load with the GeneXpert HIV-1 Viral Load assay 
(Cepheid, Sunnyvale, CA, USA), with viral suppression 
defined as fewer than 1000 HIV RNA copies per ml (as 
per WHO guidelines).
DXA scans of the lumbar spine and total body were 
done by one of two trained radiographers according 
to standard procedures on a Hologic QDR Wi densi-
tometer (Hologic, Bedford, MA, USA) with Apex software 
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(version 4.5)15 for scan analysis. Daily calibration was done 
with the manufacturer-provided spine phantom. DXA 
scans were repeated in a subgroup (n=30) selected by 
convenience sampling to confirm reproducibility. The 
precision error was a root mean square deviation of 
0·011 g/cm² (lumbar spine) and 0·010 g/cm² (total body) 
with a coefficient of variation of 1·35% (lumbar spine) and 
1·22% (total body). As mentioned, an important limitation 
of DXA in paediatric populations with chronic disease is 
that the two-dimensional (areal) bone density values are 
highly dependent on bone size; thus DXA underestimates 
bone density in small children.10 We therefore used the 
two main size-adjustment techniques recommended by 
the International Society for Clinical Densitometry (ISCD) 
to overcome the size dependence of DXA measurement:16 
we measured total-body less-head bone mineral content 
for lean mass adjusted for height (TBLH-BMCLBM), and 
lumbar spine bone mineral apparent density (LS-BMAD). 
LS-BMAD was calculated from DXA-measured lumbar 
spine data with the Carter method.17 TBLH-BMCLBM was 
calculated from the whole body scan with published 
derived equations for Hologic DXA scans, which adjust 
for log-transformed total body lean mass, total body fat 
mass, height, and age.18 Sex-matched and age-matched 
Z-scores were generated with Hologic UK population 
reference data from 1996–2012 in 4–20-year-olds as 
recommended by ISCD guidelines, as no local reference 
data were available.16 Low TBLH-BMCLBM and LS-BMAD 
were defined by a Z-score of less than –2·0.18
Statistical analysis 
A sample size of 300 in each group was required to 
permit detection of a difference between children with 
and without HIV in DXA-measured size-adjusted bone 
density Z-scores of 0·23, with 80% power and a 
significance level of 0·05 assuming an SD of 1·3.19 The 
study had 80% power to detect a 4·8% difference in 
prevalence of low TBLH-BMCLBM between children with 
and without HIV, assuming a prevalence in those 
without HIV of 1·0%.20
Height-for-age and weight-for-age Z-scores were 
calculated with 1990 UK reference data,21 with Z-scores 
of less than –2·0 defining stunting (height-for-age 
score) and underweight (weight-for-age score). We 
Figure 1: Recruitment of study participants
ART=antiretroviral therapy. DXA=dual-energy X-ray absorptiometry. *Handwritten class registers were used to identify children and sometimes listed an incorrect 
date of birth; therefore some children outside the 8–16 years age range were sent letters. †Children underwent HIV testing after enrolment. ‡All enrolled children 
were included in the final analyses unless withdrawn from the study; when children had missing data, multiple imputation methods were used.
536 children aged 8–16 randomly selected
 to receive letters
36 not eligible
 15 not living in Harare
 17 younger than 8 years or older than 16 years* 
 4 with established HIV infection and on ART >2 years
500 eligible
193 without consent 
 151 did not return letter
 42 with guardian or child refusal
307 with consent to participate
307 enrolled
13 without DXA scan due to maintenance
   1 withdrawn due to new HIV diagnosis†
293 with DXA results‡
631 children aged 8–16 years attending 
 HIV clinics
145 not eligible
 52 on ART for <2 years
 72 not living in Harare
 20 unaware of HIV status
 1 with acute illness
490 eligible
 486 identified at HIV clinics
 4 identified at schools
185 without consent
 98 with guardian or child refusal
 87 without a guardian present
305 with consent to participate
2 withdrawn
303 enrolled
24 without DXA scan due to maintenance
279 with DXA results‡
Recruitment of children without HIV (schools) Recruitment of children with HIV (clinics)
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derived socioeconomic status using the first component 
from a principal component analysis combining an 
asset list (detailing number in the household, head of 
household age, highest maternal and paternal education 
levels, household ownership, monthly household in-
come, access to amenities [electricity, water, and a flush 
toilet or pit latrine], and household item ownership 
[ fridge, bicycle, car, and television or radio]). Socio-
economic status was split into tertiles (low, middle, and 
high) for analysis.
Analyses were done with Stata (version 16.1). The 
primary exposure was HIV, and primary outcomes were 
TBLH-BMCLBM and LS-BMAD Z-scores. We compared 
participant characteristics between those with and 
without HIV using independent sample t-tests for means, 
Wilcoxon signed-rank tests for non-parametric variables, 
and χ² or Fisher’s exact tests for proportions. The same 
methods were used to compare children with and without 
missing data. To first understand the role of sex, puberty, 
and HIV on bone outcomes, we examined mean 
difference in TBLH-BMCLBM and LS-BMAD Z-scores 
between participants with and without HIV using linear 
regression with robust standard errors, overall and 
stratified by sex, Tanner stage (stages 1 and 2 vs stages 3–5), 
and age group (8–10 years, 11–13 years, and 14–16 years). 
Similarly, we examined mean risk difference for low 
TBLH-BMCLBM and low LS-BMAD Z-scores (less than –2 
vs –2 or higher) using generalised linear models, with 
Poisson distributions and log links with robust standard 
errors. The models were adjusted for age, sex, and 
pubertal stage. Mean differences were estimated with 
95% CIs. Three-way interactions between sex, pubertal 
stage, and HIV were assessed with Wald tests in linear 
regression models. In secondary analyses of absolute 
measures of TBLH-BMCLBM and LS-BMAD, generalised 
linear models with log link and gamma distri bution were 
used, and marginal means and marginal mean 
differences with 95% CIs estimated.
Associations between potential risk factors and 
TBLH-BMCLBM and LS-BMAD Z-scores were investigated 
with linear regression separately for participants with 
and without HIV. Adjustment was made for a priori 
confounders (age, sex, and pubertal stage22), potential 
risk factors (socioeconomic status,23 physical activity,24 
calcium and vitamin D intake,25 and, in those with HIV, 
CD4 cell count, viral load, tenofovir disoproxil fumarate 
[TDF] exposure, and age at ART initiation26), variables 
associated in complete case analysis with TBLH-BMCLBM 
or LS-BMAD Z-score (at p<0·20), and variables associated 
with missing status.
All enrolled children were included in the analyses. To 
account for missing data, including DXA-measured 
outcomes, we used multiple imputation by chained 
equations with seven imputed datasets, which allowed for 
imputation of categorical and continuous data jointly. 
It was assumed that data were missing at random. 
Our imputation models included all outcomes, auxiliary 
variables associated with missingness and with study 
group (with or without HIV), and variables identified in 
complete case analysis to be associated with TBLH-BMCLBM 
or LS-BMAD Z-score (p<0·20). In all analyses, the 
significance level was 0·05.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 








Age, years 303; 12·4 (2·5) 306; 12·5 (2·5) 0·69
Female sex 303; 151 (50%) 306; 155 (51%) 0·84
Socioeconomic status
Low: tertile 1 303; 115 (38%) 306; 88 (29%) ··
Middle: tertile 2 303; 105 (35%) 306; 98 (32%) ··
High: tertile 3 303; 83 (27%) 306; 120 (39%) 0·0051
Orphanhood (one or both parents dead) 290; 123 (42%) 303; 20 (7%) <0·0001
Past or current tuberculosis 302; 49 (16%) 305; 2 (1%) <0·0001
Lifestyle factors
Outdoor time, >2 h/day 303; 224 (74%) 306; 171 (56%) <0·0001
Physical activity level
Low: <600 MET minutes per week 303; 148 (49%) 306; 114 (37%) ··
Moderate: 600–3000 MET minutes per 
week
303; 77 (25%) 306; 88 (29%) ··
High: >3000 MET minutes per week 303; 78 (26%) 306; 104 (34%) 0·012
Daily dietary calcium intake
Very low: <150 mg/day 303; 135 (45%) 306; 136 (44%) ··
Low: 150–299 mg/day 303; 62 (20%) 306; 66 (22%) ··
Moderate: 300–450 mg/day 303; 106 (35%) 306; 104 (34%) 0·94
Daily dietary vitamin D intake
Very low: <4·0 μg/day 303; 40 (13%) 306; 37 (12%) ··
Low: 4·0–5·9 μg/day 303; 205 (68%) 306; 197 (64%) ··
Moderate: 6·0–7·9 μg/day 303; 58 (19%) 306; 72 (24%) 0·41
Puberty characteristics
Pubertal stage
Tanner 1 287; 117 (41%) 303; 69 (23%) ··
Tanner 2 287; 59 (21%) 303; 69 (23%) ··
Tanner 3 287; 55 (19%) 303; 53 (17%) ··
Tanner 4 287; 44 (15%) 303; 92 (30%) ··
Tanner 5 287; 12 (4%) 303; 20 (7%) <0·0001
Pubertal delay* 127; 8 (6%) 132; 0 0·0034
HIV characteristics
Age at HIV diagnosis, years 303; 3·0 (1·2–5·8) NA ··
Age at ART initiation, years 303; 3·7 (1·8–6·9) NA ··
ART duration, years 303; 8·1 (6·2–9·5) NA ··
Proportion of life on ART, % 303; 65·4% (22·1) NA ··
Current tenofovir disoproxil fumarate use 303; 102 (34%) NA ··
Viral load <1000 RNA copies per ml 268; 212 (79%) NA ··
CD4 count <500 cells per µL 288; 58 (20%) NA ··
(Table 1 continues on next page)
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Results 
Among 631 children with HIV attending clinics, 486 (77%) 
were eligible for enrolment. Four additional children with 
HIV, identified from screening in schools, met the 
inclusion criteria. Of these 490 eligible children, 303 (62%) 
were enrolled (figure 1). For most children with HIV who 
were eligible but did not enrol, the reason was refusal by 
the child or guardian, or no guardian being present. 
Compared with these children with HIV who were eligible 
but not enrolled, study participants with HIV were a mean 
of 1·2 years (SE 0·3) older, more commonly girls 
(151 [50%] of 303 enrolled vs 75 [40%] of 187 excluded), and 
more likely to attend school (295 [97%] vs 168 [90%]). Of 
536 children randomly selected from schools, 500 (93%) 
were eligible, of whom 307 (61%) consented to participate. 
One was excluded after testing HIV-positive, giving a total 
of 306 participants without HIV (mean age 12·5 [2·5] years; 
155 [51%] girls). Compared with children without HIV 
who were eligible but not enrolled, study participants 
without HIV were a mean of 0·6 years (SE 0·2) older. Sex 
distribution was similar (by number of girls, 155 [51%] of 
306 enrolled vs 95 [49%] of 194 excluded). The mean age 
of enrolled children with HIV was 12·4 years [SD 2·5], 
and 151 [50%] were girls. The mean age of enrolled 
children without HIV was 12·5 years [2·5], and 155 [51%] 
were girls (table 1).
Compared with children without HIV, a significantly 
higher proportion of children with HIV were of low 
socioeconomic status, were orphaned, had past or current 
tuberculosis, were less physically active, and reported 
spending more time outdoors (table 1). Across the whole 
study population, consumption of vitamin D and calcium 
was low, with 479 (79%) of 609 children consuming less 
than 6·0 μg/day vitamin D (US National Institutes of 
Health recommended daily allowance [RDA] ≥15 μg/day), 
and 399 (66%) consuming less than 300 mg/day of 
calcium (RDA ≥1300 mg/day). No participants reported 
smoking, drinking alcohol, or oral steroid use at the time 
of enrolment. The 24 children with HIV and 14 children 
without HIV who were missing DXA data (figure 1) were 
thinner (based on BMI Z-score <2) and shorter (based 
on standing height Z-score) than those with DXA data 
(appendix p 1). Additionally, orphanhood status and 
earlier pubertal stage were associated with missingness 
of data when considering all outcomes and covariates 
(appendix pp 1–2).
Five (2%) of the 303 children with HIV were not 
perinatally infected. The median age of HIV diagnosis was 
3·0 years (IQR 1·2–5·8), with ART initiated at a median 
age of 3·7 years (1·8–6·9; table 1). Median ART duration 
was 8·1 (IQR 6·2–9·5) years. At enrolment, 102 (34%) of 
303 children were on a TDF regimen, with a median 
duration of TDF use of 3·0 years (IQR 1·4–5·5). Overall, 
211 children (70%) were taking a non-nucleoside reverse-
tran scriptase inhibitor ART regimen, and 89 (29%) a 
protease inhibitor ART regimen. The median CD4 count 
was 766 cells per µl (IQR 537–1019), and 212 children (79%) 
had a suppressed HIV viral load (table 1).
Compared with children without HIV, a significantly 
higher proportion of children with HIV had stunted 
growth (97 [32%] of 302 with available data vs 24 [8%] 
of 306; p<0·0001) and were underweight (79 [26%] of 303 
vs 26 [9%] of 304 with available data; p<0·0001; table 1). 
The height differences between children with and 
without HIV were greater for standing height than for 
sitting height (mean Z-score difference 1·05 [95% CI 
0·87–1·24] for standing height and 0·73 [0·55–0·92] for 
sitting height). Compared with children without HIV, 
children with HIV were more likely to be at an earlier 
Tanner stage, and, among older girls (≥13 years) and 
older boys (≥14 years), to have pubertal delay (8 [6%] of 
127 with available data vs 0 of 132 with available data; 
p=0·0034; table 1; appendix p 3).
DXA-based measures were available in 279 children 
with HIV and 293 children without HIV (figure 1). In 
children with HIV, LS-BMAD was available in 293 children 
and TBLH-BMCLBM in 292 (table 1). Mean TBLH-BMCLBM 
and LS-BMAD, in terms of absolute values and Z-scores, 
were lower in children with HIV than in those without 
HIV. Children with HIV had a higher prevalence of 
low TBLH-BMCLBM Z-score than children without HIV 
(29 [10%] of 279 vs 18 [6%] of 292; p=0·066) and a higher 
prevalence of low LS-BMAD Z-score (40 [14%] of 279 vs 
17 [6%] of 293; p=0·0007; table 1). Overall, children with 
HIV had a 0·20 (95% CI 0·03–0·37) lower TBLH-BMCLBM 






(Continued from previous page)
Anthropometry
Standing height Z-score 302; –1·68 (1·23) 306; –0·63 (1·08) <0·0001
Height-for-age Z-score less than –2† 302; 97 (32%) 306; 24 (8%) <0·0001
Sitting height for age Z-score 303; –2·11 (1·12) 303; –1·38 (1·21) <0·0001
Sitting height-for-age Z-score less than –2 303; 152 (50%) 303; 76 (25%) <0·0001
Weight-for-age Z-score 303; –1·46 (1·20) 304; –0·55 (1·24) <0·0001
Weight-for-age Z-score less than –2‡ 303; 79 (26%) 304; 26 (9%) <0·0001
BMI Z-score 302; –0·63 (1·01) 304; –0·28 (1·17) <0·0001
BMI Z-score less than –2 302; 28 (9%) 304; 18 (6%) 0·12
Bone density measures
TBLH-BMCLBM, g 279; 950·9 (272·8) 292§; 1090·3 (336·1) <0·0001
TBLH-BMCLBM Z-score 279; –0·61 (1·08) 292§; –0·41 (1·00) 0·018
TBLH-BMCLBM Z-score less than –2 279; 29 (10%) 292§; 18 (6%) 0·066
LS-BMAD, g/cm³ 279; 0·202 (0·035) 293; 0·210 (0·037) 0·013
LS-BMAD Z-score 279; –0·51 (1·40) 293; –0·24 (1·21) 0·014
LS-BMAD Z-score less than –2 279; 40 (14%) 293; 17 (6%) 0·0007
Data are available sample; n (%), available sample; mean (SD), or available sample; median (IQR). MET=resting 
metabolic rate. ART=antiretroviral therapy. BMI=body-mass index. TBLH-BMCLBM=total body less head bone mineral 
content for lean mass adjusted for height. LS-BMAD=lumbar spine bone mineral apparent density. *Definition of 
pubertal delay (lower than Tanner stage 2) applicable for girls aged 13 years or older and boys aged 14 years or older. 
†Defined as stunted growth. ‡Defined as underweight. §Missing data from one participant who had both lumbar spine 
and total body scans but the total body scan could not be analysed due to a software analysis error.
Table 1: Characteristics of study participants
See Online for appendix
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than children without HIV, in terms of crude mean 
difference (table 2). Differences in LS-BMAD Z-score were 
similar in girls and boys, whereas differences in 
TBLH-BMCLBM Z-score were more apparent in girls. Both 
boys and girls with HIV had an increased risk of low 
LS-BMAD Z-score, with boys in early puberty showing the 
greatest risk of low Z-score (table 2). In children with 
HIV, low LS-BMAD was associated with stunting; this 
association was not observed in children without HIV 
(appendix p 4).
In each age group (8–10 years, 11–13 years, and 
14–16 years), both male and female children with HIV 
were at an earlier Tanner stage than their HIV-negative 
peers of the same sex (appendix p 3). Mean absolute values 
of TBLH-BMCLBM and LS-BMAD differed by pubertal stage 
and sex (three-way interactions: TBLH-BMCLBM p=0·041, 
LS-BMAD p=0·88), such that differences in absolute and 
Z-score values for TBLH-BMCLBM and LS-BMAD between 
participants with and without HIV were most marked in 
the late pubertal stages (figure 2). Differences in size-
adjusted bone density between participants with and 
without HIV were generally small in the early stages of 
puberty (table 2). In the later stages of puberty, differences 
in bone outcomes between those with and without HIV 
were more apparent for both sexes, except for TBLH-
BMCLBM Z-score in boys. Girls particularly showed evidence 
of differences in TBLH-BMCLBM and LS-BMAD for 
Z-scores and absolute values (figure 2, table 2). Stratifi-
cation by age group, sex, and pubertal stage caused wide 
confidence intervals (figure 2) as few older participants 
with HIV (14–16 years) were in the late stages of puberty 
(Tanner stages 4 and 5), compared with participants of the 
same age without HIV (appendix p 3). When models 
assessing differences in TBLH-BMCLBM and LS-BMAD 
Z-scores between children with and without HIV were 
adjusted for age, sex, and pubertal stage, the Z-score 
differences were marginally decreased (–0·13 [95% CI 
–0·31 to 0·05] for TBLH-BMCLBM Z-score and –0·11 [–0·32 
to 0·11] for LS-BMAD Z-score). However, even after 
adjustment for age, male children with HIV in the early 
stages of puberty had a greater risk of low LS-BMAD than 
did males without HIV (risk difference 0·14 [95% CI 
0·04–0·24]; table 2).
Among children without HIV, male sex (vs female sex) 
and earlier pubertal stage (vs later pubertal stage) were 
associated with lower TBLH-BMCLBM and LS-BMAD 
Z-scores in crude analysis, but not in the adjusted 
analysis (appendix pp 5–6). Among children with HIV, 
being an orphan (vs not an orphan) and TDF exposure 
(vs non-exposure) were associated with lower TBLH-
BMCLBM Z-score in unadjusted analysis and after adjust-
ment for age, sex, pubertal stage, socioeconomic status, 
physical activity, calcium and vitamin D intake, CD4 cell 
count, HIV viral load, age at ART initiation, orphanhood 
status, and TDF exposure (table 3). After adjustment, 
TDF exposure for 4 or more years (vs no exposure) was 
associated with a 0·52 (95% CI 1·04 to 0·003; p=0·046) 
n* Crude mean difference† (Z-scores) 
or crude risk difference‡ (low 
Z-scores)
Adjusted mean difference†§ 
(Z-scores) or adjusted risk 
difference‡§ (low Z-scores)
TBLH-BMCLBM Z-score
Overall¶ 609 –0·20 (–0·37 to –0·03) –0·13 (–0·31 to 0·05)
Boys|| 303 –0·12 (–0·36 to 0·11) –0·06 (–0·30 to 0·18)
Girls|| 306 –0·27 (–0·52 to –0·02) –0·20 (–0·46 to 0·06)
Boys
Tanner stage 1–2** 175 –0·18 (–0·49 to 0·12) –0·17 (–0·47 to 0·14)
Tanner stage 3–5** 117 –0·12 (–0·50 to 0·26) –0·11 (–0·50 to 0·27)
Girls
Tanner stage 1–2** 139 –0·14 (–0·50 to 0·22) –0·12 (–0·48 to 0·23)
Tanner stage 3–5** 159 –0·35 (–0·71 to 0·01) –0·34 (–0·70 to 0·03)
LS-BMAD Z-score
Overall¶ 609 –0·26 (–0·48 to –0·04) –0·11 (–0·32 to 0·11)
Boys|| 303 –0·27 (–0·58 to 0·04) –0·17 (–0·46 to 0·13)
Girls|| 306 –0·23 (–0·51 to 0·04) –0·04 (–0·32 to 0·24)
Boys
Tanner stage 1–2** 175 –0·29 (–0·68 to 0·10) –0·16 (–0·54 to 0·22)
Tanner stage 3–5** 117 –0·44 (–0·95 to 0·07) –0·46 (–0·95 to 0·03)
Girls
Tanner stage 1–2** 139 –0·09 (–0·53 to 0·34) 0·00 (–0·42 to 0·42)
Tanner stage 3–5** 159 –0·30 (–0·66 to 0·07) –0·24 (–0·61 to 0·13)
TBLH-BMCLBM low Z-score (less than –2)
Overall¶ 609 0·04 (–0·005 to 0·08) 0·01 (–0·03 to 0·05)
Boys|| 303 0·05 (–0·01 to 0·11) 0·02 (–0·03 to 0·07)
Girls|| 306 0·02 (–0·04 to 0·08) 0·00 (–0·04 to 0·05)
Boys
Tanner stage 1–2** 175 0·04 (–0·03 to 0·12) 0·04 (–0·05 to 0·13)
Tanner stage 3–5** 117 0·05 (–0·05 to 0·16) 0·04 (–0·04 to 0·12)
Girls
Tanner stage 1–2** 139 0·00 (–0·09 to 0·10) –0·01 (–0·13 to 0·12)
Tanner stage 3–5** 159 0·03 (–0·04 to 0·11) 0·02 (–0·04 to 0·09)
LS-BMAD low Z-score (less than –2)
Overall¶ 609 0·08 (0·03 to 0·12) 0·02 (–0·02 to 0·06)
Boys|| 303 0·09 (0·01 to 0·17) 0·03 (–0·03 to 0·09)
Girls|| 306 0·06 (0·01 to 0·11) 0·02 (–0·01 to 0·05)
Boys
Tanner stage 1–2** 175 0·13 (0·05 to 0·22) 0·14 (0·04 to 0·24)
Tanner stage 3–5** 117 0·07 (–0·09 to 0·23) 0·04 (–0·06 to 0·13)
Girls
Tanner stage 1–2** 139 0·08 (0·00 to 0·17) 0·09 (–0·03 to 0·21)
Tanner stage 3–5** 159 0·03 (–0·03 to 0·08) 0·01 (–0·02 to 0·04)
Values in parentheses are 95% CIs. Negative mean difference values indicate a lower mean in children with HIV; positive 
risk difference values indicate an increased risk of low Z-score (less than –2·0) in children with HIV. TBLH-BMCLBM=total body 
less head bone mineral content for lean mass adjusted for height. LS-BMAD=lumbar spine bone mineral apparent density. 
*Non-missing data; the missing data for TBLH-BMCLBM Z-score (19 boys and 19 girls), LS-BMAD Z-score (18 boys and 
19 girls), pubertal stage (11 boys and eight girls), and orphanhood (nine boys and seven girls) were estimated with 
multiple imputation models and numbers in each pubertal stage stratum varied by imputation dataset. †Linear regression 
with robust standard errors. ‡Generalised linear model, Poisson distribution, and log link with robust standard errors. 
§Model adjusted for age, sex, and pubertal stage. ¶Tanner stage included as a variable with five levels. ||Estimated by 
fitting an interaction term for sex by HIV status; in models adjusted for Tanner stage (as five levels). **Estimated by fitting 
a three-way interaction term for sex by Tanner stage (two categories) and HIV status.
Table 2: Mean difference in Z-scores and risk difference in low Z-scores between children with and 
without HIV
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SD deficit in TBLH-BMCLBM Z-score, and orphanhood 
with a 0·46 (0·75 to 0·17; p=0·0023) SD deficit.
Older age (vs younger age), male sex (vs female sex), 
being an orphan (vs not an orphan), older age at ART 
initiation (vs younger age at initiation), and TDF exposure 
were all associated with lower LS-BMAD Z-score in 
unadjusted analysis (table 4). A weak association was 
detected between low CD4 cell count and low LS-BMAD 
Z-score. Older age and male sex remained associated, and 
earlier Tanner stage (vs later Tanner stage) showed an 
association, with low LS-BMAD Z-score after adjustment 
for orphanhood, socioeconomic status, physical activity, 
calcium and vitamin D intake, ART initiation, TDF 
exposure, CD4 count, viral load as well as age, sex, and 
pubertal stage.
Current TDF use was associated with a 0·41 (95% CI 
0·08–0·74; p=0·015) lower TBLH-BMCLBM Z-score 
and 0·31 (0·08–0·69; p=0·12) lower LS-BMAD Z-score, 
compared with Z-scores in children with HIV on 
non-TDF-based ART, after adjustment for age, sex, 
pubertal stage, orphanhood, socioeconomic status, 
physical activity, calcium and vitamin D intake, CD4 cell 
count, HIV viral load, and age at ART initiation.
Discussion 
The main finding of this study was that despite ART, 
marked deficits in size-adjusted bone density are common 
among children with HIV, who have a substantially 
higher prevalence of low bone density (a deficit of 2 SDs 
or more from reference mean values) than their peers 
Figure 2: Mean values for (A) TBLH-BMCLBM Z-score, (B) LS-BMAD Z-score, (C) absolute TBLH-BMCLBM, and (D) absolute LS-BMAD, stratified by sex, age, pubertal stage, and HIV status
Unadjusted data are shown. Error bars indicate 95% CIs. Raw data are presented as open circles (HIV-positive) and open triangles (HIV-negative). TBLH-BMCLBM=total body less head bone mineral 
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Crude β coefficient 
(95% CI)‡




8–10 years 94 –0·58 1 (ref) ·· 1 (ref) ··
11–13 years 94 –0·48 0·13 (–0·18 to 0·43) ·· 0·16 (–0·27 to 0·58) ··
14–16 years 91 –0·78 –0·16 (–0·48 to 0·15) 0·20 –0·15 (–0·73 to 0·44) 0·32
Sex
Male 142 –0·69 1 (ref) ·· 1 (ref) ··
Female 137 –0·53 0·14 (–0·13 to 0·40) 0·30 0·12 (–0·14 to 0·38) 0·36
Pubertal stage
Tanner 1 107 –0·63 1 (ref) ·· 1 (ref) ··
Tanner 2 56 –0·74 –0·07 (–0·43 to 0·29) ·· 0·08 (–0·32 to 0·49) ··
Tanner 3 49 –0·67 –0·02 (–0·37 to 0·33) ·· 0·02 (–0·46 to 0·51) ··
Tanner 4 40 –0·51 0·12 (–0·34 to 0·58) ·· 0·45 (–0·18 to 1·08) ··
Tanner 5 12 –0·64 –0·05 (–0·70 to 0·59) 0·95 0·20 (–0·60 to 1·01) 0·52
Socioeconomic status
High: tertile 3 78 –0·62 1 (ref) ·· 1 (ref) ··
Middle: tertile 2 93 –0·64 –0·02 (–0·35 to 0·30) ·· 0·03 (–0·26 to 0·39) ··
Low: tertile 1 108 –0·58 0·05 (–0·27 to 0·38) 0·87 0·06 (–0·26 to 0·39) 0·93
Orphanhood
Not an orphan 154 –0·42 1 (ref) ·· 1 (ref) ··
One or both parents dead 113 –0·84 –0·45 (–0·71 to –0·18) 0·0011 –0·46 (–0·75 to –0·17) 0·0023
Physical activity level
High: >3000 MET minutes per week 76 –0·53 1 (ref) ·· 1 (ref) ··
Moderate: 600–3000 MET minutes per week 69 –0·62 –0·09 (–0·43 to 0·26) ·· 0·02 (–0·34 to 0·37) ··
Low: <600 MET minutes per week 134 –0·65 –0·13 (–0·44 to 0·18) 0·71 –0·03 (–0·35 to 0·29) 0·96
Daily dietary calcium intake
Moderate: 300–450 mg/day 95 –0·70 1 (ref) ·· 1 (ref) ··
Low: 150–299 mg/day 60 –0·64 0·07 (–0·28 to 0·42) ·· 0·11 (–0·26 to 0·47) ··
Very low: <150 mg/day 124 –0·53 0·20 (–0·09 to 0·48) 0·39 0·24 (–0·06 to 0·53) 0·30
Daily dietary vitamin D intake
Moderate: 6·0–7·9 μg/day 50 –0·40 1 (ref) ·· 1 (ref) ··
Low: 4·0–5·9 μg/day 190 –0·62 –0·18 (–0·51 to 0·15) ·· –0·25 (–0·58 to 0·09) ··
Very low: <4·0 μg/day 39 –0·82 –0·38 (–0·83 to 0·06) 0·25 –0·50 (–0·96 to –0·03) 0·11
CD4 count
≥500 cells per µL 213 –0·59 1 (ref) ·· 1 (ref) ··
<500 cells per µL 54 –0·70 –0·08 (–0·40 to 0·24) 0·64 –0·07 (–0·42 to 0·28) 0·71
HIV viral load
≥1000 RNA copies per ml 54 –0·53 1 (ref) ·· 1 (ref) ··
<1000 RNA copies per ml 207 –0·65 –0·16 (–0·47 to 0·15) 0·30 –0·24 (–0·60 to 0·12) 0·19
Age at ART initiation
<4 years 148 –0·61 1 (ref) ·· 1 (ref) ··
4–8 years 83 –0·58 0·04 (–0·27 to 0·35) ·· 0·11 (–0·23 to 0·45) ··
>8 years 48 –0·68 –0·02 (–0·37 to 0·33) 0·94 0·21 (–0·21 to 0·63) 0·62
TDF years of exposure
None 184 –0·48 1 (ref) ·· 1 (ref) ··
<4 years 59 –0·80 –0·30 (–0·61 to 0·02) ·· –0·35 (–0·69 to 0·0003) ··
≥4 years 36 –0·95 –0·48 (–0·93 to –0·02) 0·037 –0·52 (–1·04 to –0·003) 0·046
TBLH-BMCLBM=total body less head bone mineral content for lean mass adjusted for height. MET=resting metabolic rate. ART=antiretroviral therapy. TDF=tenofovir disoproxil 
fumarate. *Non-missing data. †Arithmetic mean of non-missing data. ‡β coefficient from linear regression indicates the Z-score difference from the reference category; 
lower values indicate lower Z-scores; missing data for TBLH-BMCLBM Z-score (n=24), lumbar spine bone mineral apparent density Z-score (n=24), pubertal stage (n=16), 
orphanhood (n=13), CD4 cell count (n=15), and HIV viral load (n=35) were estimated with multiple imputation models. §Adjusted model includes age, sex, pubertal stage, 
orphanhood, socioeconomic status, physical activity, calcium and vitamin D intake, age at ART initiation, years of TDF exposure, CD4 cell count, and viral load.
Table 3: Characteristics associated with TBLH-BMCLBM Z-score in participants with HIV
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8–10 years 94 –0·11 1 (ref) ·· 1 (ref) ··
11–13 years 94 –0·31 –0·24 (–0·62 to 0·13) ·· –0·36 (–0·86 to 0·15) ··
14–16 years 91 –1·13 –0·99 (–1·34 to –0·60) <0·0001 –1·26 (–1·96 to –0·55) 0·0012
Sex
Male 142 –0·89 1 (ref) ·· 1 (ref) ··
Female 137 –0·12 0·76 (0·43 to 1·08) <0·0001 0·77 (0·45 to 1·09) <0·0001
Pubertal stage
Tanner 1 117 –0·37 1 (ref) ·· 1 (ref) ··
Tanner 2 59 –0·65 –0·30 (–0·75 to 0·15) ·· 0·38 (–0·12 to 0·88) ··
Tanner 3 55 –0·51 –0·16 (–0·62 to 0·30) ·· 0·56 (–0·01 to 1·13) ··
Tanner 4 44 –0·70 –0·32 (–0·89 to 0·25) ·· 1·05 (0·32 to 1·78) ··
Tanner 5 12 –0·56 –0·29 (–1·14 to 0·57) 0·67 1·31 (0·36 to 2·25) 0·029
Socioeconomic status
High: tertile 3 78 –0·48 1 (ref) ·· 1 (ref) ··
Middle: tertile 2 (middle) 93 –0·49 –0·02 (–0·43 to 0·40) ·· 0·02 (–0·36 to 0·41) ··
Low: tertile 1 108 –0·56 –0·09 (–0·51 to 0·32) 0·89 –0·14 (–0·55 to 0·26) 0·65
Orphanhood
Not an orphan 154 –0·32 1 (ref) ·· 1 (ref) ··
One or both parents dead 113 –0·77 –0·44 (–0·77 to –0·11) 0·010 –0·25 (–0·59 to 0·09) 0·14
Physical activity level
High: >3000 MET minutes per week 76 –0·38 1 (ref) ·· 1 (ref) ··
Moderate: 600–3000 MET minutes per week 69 –0·60 –0·23 (–0·68 to 0·22) ·· –0·15 (–0·58 to 0·28) ··
Low: <600 MET minutes per week 134 –0·55 –0·15 (–0·54 to 0·25) 0·39 –0·11 (–0·50 to 0·28) 0·77
Daily dietary calcium intake
Moderate: 300–450 mg/day 95 –0·38 1 (ref) ·· 1 (ref) ··
Low: 150–299 mg/day 60 –0·46 –0·07 (–0·53 to 0·39) ·· –0·05 (–0·50 to 0·41) ··
Very low: <150 mg/day 124 –0·64 –0·23 (–0·59 to 0·14) 0·46 –0·16 (–0·51 to 0·20) 0·69
Daily dietary vitamin D intake
Moderate: 6·0–7·9 μg/day 50 –0·22 1 (ref) ·· 1 (ref) ··
Low: 4·0–5·9 μg/day 190 –0·56 –0·36 (–0·95 to 0·23) ·· –0·28 (–0·74 to 0·18) ··
Very low: <4·0 μg/day 39 –0·64 –0·27 (–0·73 to 0·19) 0·40 –0·20 (–0·79 to 0·39) 0·42
CD4 count
>500 cells per µL 213 –0·43 1 (ref) ·· 1 (ref) ··
<500 cells per µL 54 –0·82 –0·39 (–0·80 to 0·02) 0·060 –0·06 (–0·48 to 0·36) 0·78
HIV viral load
>1000 RNA copies per mL 54 –0·71 1 (ref) ·· 1 (ref) ··
<1000 RNA copies per mL 207 –0·45 0·26 (–0·15 to 0·68) 0·21 0·07 (–0·34 to 0·48) 0·75
Age at ART initiation
<4 years 148 –0·18 1 (ref) ·· 1 (ref) ··
4–8 years 83 –0·79 –0·61 (–0·99 to –0·24) ·· –0·28 (–0·69 to 0·13) ··
>8 years 48 –1·06 –0·83 (–1·27 to –0·38) <0·0001 –0·36 (–0·86 to 0·15) 0·29
TDF years of exposure
None 184 –0·26 1 (ref) ·· 1 (ref) ··
<4 years 59 –0·97 –0·70 (–1·11 to –0·29) ·· –0·38 (–0·81 to 0·05) ··
≥4 years 36 –1·04 –0·72 (–1·25 to –0·19) <0·0001 –0·19 (–0·75 to 0·38) 0·25
LS-BMAD=lumbar spine bone mineral apparent density. MET=resting metabolic rate. ART=antiretroviral therapy. TDF=tenofovir disoproxil fumarate. *Non-missing data. 
†Arithmetic mean of non-missing data. ‡β coefficient from linear regression indicates the Z-score difference from the reference category; lower values indicate lower 
Z-scores; missing data for total-body less-head bone mineral content for lean mass adjusted for height Z-score (n=24), LS-BMAD Z-score (n=24), pubertal stage (n=16), 
orphanhood (n=13), CD4 cell count (n=15), and HIV viral load (n=35) were estimated with multiple imputation models. §Adjusted model includes age, sex, pubertal stage, 
orphanhood, socioeconomic status, physical activity, calcium and vitamin D intake, age at ART initiation, years of TDF exposure, CD4 cell count, and viral load.
Table 4: Characteristics associated with LS-BMAD Z-score in participants with HIV
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without HIV. The negative associations between HIV and 
size-adjusted bone density were more pronounced with 
pubertal maturation. Orphanhood and use of tenofovir 
were associated with the bone deficits in peripubertal 
children with HIV.
Across all age groups, children with HIV showed 
delayed pubertal stage compared with their peers without 
HIV. Despite low numbers, the association between HIV 
and size-adjusted bone density was most marked towards 
the end of puberty. This finding suggests cumulatively 
lower bone accrual throughout puberty in children with 
HIV, relative to children without HIV. Importantly, if bone 
accrual remains compromised, children with HIV will 
reach substantially lower PBM in adulthood. Girls with 
HIV had substantially lower TBLH-BMCLBM Z-scores than 
girls without HIV, which became most apparent in later 
puberty; this level of deficit was not seen in boys. Both 
male and female children with HIV had lower LS-BMAD 
Z-scores and a greater risk of low LS-BMAD (ie, Z-score 
less than –2) than those without HIV. Boys with HIV in 
early puberty were at the greatest risk of low LS-BMAD. 
These results highlight the need for interventions to 
optimise bone density before skeletal growth is completed. 
A number of interventions might be beneficial. In 
Zimbabwe and Zambia, a trial is underway to assess 
whether supplementation of vitamin D3 and calcium 
ameliorates bone mineralisation deficits in adolescents 
growing up with HIV (Pan African Clinical Trials Registry 
number PACTR202009897660297). Further more, our 
study identified lower physical activity in children with 
HIV than in their uninfected peers. High impact physical 
activity is thought to be osteogenic, and has been 
associated with improved bone density at the hip in 
healthy adolescents.24 In 2021, a small randomised trial 
in young adults living with HIV suggested that a 
combination of resistance and aerobic exercise might 
improve bone mass;27 whether the same is applicable for 
children with HIV remains to be confirmed. In 2019, 
the first small randomised controlled trial of the oral 
bisphosphonate, alendronate, given to children with HIV, 
showed some evidence of improved bone density over 
48 weeks of treatment;28 however, longer term effects on 
PBM, fracture risk, and rare side-effects are unknown.
The deficits we identified in TBLH-BMCLBM in girls 
at the end of puberty is a concern. Bone density is 
compromised during pregnancy and lactation when 
skeletal calcium reserves are mobilised,29 and even 
healthy adolescent mothers might have a compromised 
PBM.30 Given that in 2019, 24% of young women living 
in Zimbabwe had given birth before the age of 18 years,31 
our findings have implications for the recovery of 
skeletal mineralisation post partum and subsequent 
adult fracture risk.32
Children with HIV had a higher prevalence of stunting 
than with uninfected children. Furthermore, a higher 
proportion of children with HIV who were stunted had 
lower lumbar spine bone density than stunted children 
without HIV. Although stunting increases the risk of poor 
skeletal growth, we have shown that stunting is not a 
sufficient clinical proxy for low size-adjusted bone density. 
Interestingly, in children with HIV, deficits in standing 
height were greater than in sitting height, suggesting that 
HIV infection might have a greater effect on appendicular 
(limb length) than axial (spinal length) skeletal growth. 
Appendicular growth occurs more rapidly than axial 
growth before puberty. Exposures directly before puberty 
might preferentially affect appendicular development, 
whereas exposures during puberty might have a greater 
effect on axial development.33 Thus, our findings suggest 
that HIV and its treatment prepubertally could be 
particularly important in influencing linear growth.
Notably, ART drugs themselves might cause accelerated 
bone loss. We observed a strong and consistent association 
between TDF exposure and bone deficits, particularly 
affecting TBLH-BMCLBM. Children exposed to TDF for 
4 or more years had, on average, a 0·52 SD deficit in 
TBLH-BMCLBM Z-score compared with children with HIV 
who had not received TDF. This finding represents a 
clinically important effect size, as a 0·5 SD reduction 
in bone density increases fracture risk by 50%, both in 
children and, if sustained, adults.34 Although bone loss 
following TDF initiation in adults is well recognised, 
studies of TDF effects on bone outcomes in children 
have been inconsistent. For example, among 74 Brazilian 
adolescents (mean age 17·3 years [SD 1·8]), increased 
duration of TDF use was associated with lower (albeit non 
size-adjusted) lumbar spine and total body bone density;35 
whereas a larger study of 394 Thai adolescents of a similar 
age (median 16·1 years [IQR 14·7–17·4) found no such 
association for (non-size adjusted) total body bone density 
or (size-adjusted) LS-BMAD.36
Our study supports the hypothesis that TDF use has a 
detrimental effect on bone health in children. Notably, 
we observed a dose response, with increased TDF 
exposure associated with pronounced bone deficits. 
TBLH-BMCLBM largely represents cortical bone (whereas 
LS-BMAD reflects predominantly trabecular bone), and 
therefore our findings suggest TDF might particularly 
affect the mineralisation of cortical bone to reduce 
density, which is consistent with TDF-induced renal 
tubulopathy with phosphaturia leading to skeletal 
hypomineralisation.37 TDF is a well tolerated drug and 
remains one of the recommended component drugs of 
a first-line ART regimen, and is thus extensively used 
in sub-Saharan Africa, in both children and adults. In 
Zimbabwe, TDF is mostly available at an adult dose as 
part of a combination ART regimen, and use is 
recommended only in children weighing more than 
25 kg or older than 10 years. However, due to limited 
availability of ART options, TDF is often prescribed in 
younger children or those of lower weight, effectively 
providing a higher than recommended dose. Our 
findings add to growing evidence supporting the 
replacement of TDF with tenofovir alafenamide, 
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a prodrug of TDF that is associated with substantially 
fewer effects on bone and kidneys.38 This issue is of 
particular importance in adolescence, a period of rapid 
bone accrual, because reaching PBM might otherwise 
be compromised by TDF use.
The mechanism by which HIV compromises musculo-
skeletal development is likely to be multifactorial. HIV 
promotes dysregulated systemic immune activation, which 
is not completely reversed by ART.39 During childhood, 
bone formation usually predominates over bone resorption, 
but the proinflammatory milieu leads to an imbalance in 
osteoblastic and osteoclastic activity, promoting increased 
bone resorption relative to formation. Other factors that 
can compromise skeletal development include inadequate 
dietary calcium, vitamin D deficiency,25 and low levels of 
physical activity.24 Although in this study, children with HIV 
reported lower physical activity than uninfected children, 
low intake of both calcium and vitamin D were common 
regardless of HIV status. Orphanhood, more common in 
children with HIV, was independently associated with low 
TBLH-BMCLBM. Orphanhood might be a proxy for social 
and emotional deprivation, which, along with biological 
and nutritional factors, could disrupt growth.
The strengths of the study were being well powered, 
the inclusion of an HIV-uninfected comparison group 
from broadly the same socioeconomic background, and 
collection of detailed data on risk factors, including 
physical activity and vitamin D and calcium intake, via a 
standardised tool adapted for the local context. ISCD-
recommended size-adjustment methods were used for 
DXA data, which were particularly crucial given height 
differences (levels of stunting) in the population studied.16,18 
In addition, sex-matched and age-matched Z-scores were 
used for size-adjusted bone density measures, which have 
greater clinical interpretability than absolute measures.
We acknowledge several limitations. Data were cross-
sectional and therefore causality cannot be inferred. In 
the absence of local or African reference population data, 
the reference data used to generate the Z-scores for 
TBLH-BMCLBM and LS-BMAD were obtained from a 
paediatric reference population in the UK, with use of 
the same DXA manufacturer and software version to 
derive Z-scores (as recommended by the ISCD).16 This 
reference population might not be comparable to the 
children in this study. Although the study population 
Z-score SDs for TBLH-BMCLBM were close to 1, those for 
LS-BMAD were further from 1, suggesting the UK 
reference population might be a better fit for total body 
data than lumbar spine data, or that the size-adjustment 
should be further validated in African populations. DXA 
is unable to distinguish between bone density deficits 
due to hypomineralisation versus other architectural 
properties of bone. Only current CD4 cell count and HIV 
viral load were available as markers of HIV disease 
severity; annual trends in these measures would be more 
appropriate as growth occurs over a long period. Only 
5 (2%) children with HIV reported non-perinatal 
infection and their inclusion is highly unlikely to have 
biased results. Aside from examining TDF versus non-
TDF ART regimens, we did not have sufficient power 
to further categorise the many ART regimens and 
examine associations with other individual treatments. 
Furthermore, although we examined three-way inter-
actions between age, puberty, and HIV on size-adjusted 
bone density, the study was not powered to detect the 
true differences between these strata. Although we aimed 
to collect comprehensive data on factors associated with 
size-adjusted bone density and growth, residual con-
founding might have been introduced by other past or 
current biological or environmental factors. Due to 
delays in engineering maintenance, DXA measurements 
were missing for a minority of children, in addition to a 
small amount of missing covariate data. We used 
multiple imputation with chained equations to impute 
these data, which were subject to a missing at random 
assumption. Our findings are therefore valid under this 
assumption and the specified imputation model. Finally, 
reaching PBM is estimated to occur in people in their 
early 20s, and therefore bone accrual might continue to 
consolidate after the age range examined.
To our knowledge, this study is the largest to investigate 
the relationship between HIV infection and skeletal 
health in children in sub-Saharan Africa in the ART era. 
Although ART results in immune reconstitution and has 
dramatically improved survival, this study highlights the 
importance of addressing the long-term adverse effects of 
HIV infection on musculoskeletal health in populations 
of children, particularly in sub-Saharan Africa. HIV 
programmes need to focus beyond delivery of ART, 
to develop strategies for prevention and management of 
the long-term effects of HIV infection, including on 
musculoskeletal health, to ensure optimum health in 
children as they enter adulthood. Longitudinal studies 
with follow-up of children during and after puberty are 
required to understand the extent of catch-up growth and 
bone accrual. Indeed, the population reported have now 
completed the 12-month follow-up in the IMVASK study 
and results are expected soon.
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